Epizyme A Buy On Firmer Tazemetostat Timeline

|
About: Epizyme, Inc. (EPZM)
by: William Meyers
This article is exclusive for subscribers.
William Meyers
Long only, tech, biotech, research analyst
Summary

Tazemetostat for epithelioid sarcoma NDA submitted to FDA on May 30.

Phase 2 data looks good.

Label expansion could be ahead as well.

Epizyme (EPZM) specializes in an epigenetic therapy approach to human diseases, including cancers. This is a new field and potentially a revolutionary one. Proving a drug from the epigenetics platform can work well